CA2265507C - Intracorporeal light treatment of blood - Google Patents

Abstract

This invention is a method and apparatus for administering intracorporeal photopheresis to blood flowing in a patient's body to destroy an undesirable component in the blood, where the undesirable component has absorbed a photoreactive agent having a characteristic light absorption wave band. The apparatus includes an implantable housing (100) that is adapted to be placed transcutaneously within a patient's body. An inlet (104), and outlet (102) for a fluid path (128) through the housing (100) are provided, and are coupled to a patient's circulator system so that they convey blood into, and out of, the housing (100). Light sources (110) disposed within the housing (100) (or externally disposed and coupled to the housing by optical fibers) emit light having a wave band substantially equal to the absorption wave band of the photoreactive agent. A portion of the fluid path (128) within the housing (100) is optically transparent so that blood is irradiated with light from the light source (110). The fluid path (128) can have one of several different configurations, including serpentine, planar coil, helical coil, and cross tubes coupling inlet and outlet header manifolds. The light source (110) can comprise light emitting diodes (LEDs) or other types of light sources, and may be coupled to the reactor through optical fibers. The power supply (800) for the light source (110) can be intracorporeal or extracorporeal.

Description

?WO 98/1424310152025CA 02265507 1999-03-08PCT/US97/14781INTRACORPOREAL LIGHT TREATMENT OF BLOODField of the InventionThe present invention generally relates to an invention for using light toadminister a medical treatment to blood, and more specifically, to apparatus and amethod for exposing blood circulating through a patient’s body to light, for thepurpose of providing a therapeutic bene?t.Background of the InventionVarious diseases of the blood, such as T-cell lymphoma, can be besttreated by a technique that affects only a selected type of organism in the blood toavoid undesired consequences relating to the other functions that blood performs.Extracorporeal photochemotherapy or photopheresis is currently a preferredtreatment for such diseases. In this therapy, heparinized venous blood is treatedwith a photosensitizing agent such as 8-methoxypsoralen (which may be ingestedorally). The photosensitizing agent, which is preferentially absorbed by abnormalor malignant T-cell lymphocytes that are to be destroyed, is circulated outside thebody and exposed to UVA light having a waveband corresponding to anabsorption waveband of the psoralen. After being exposed to the light source, theblood is returned to the patient’s body. The extracorporeal photodynamic therapy(PDT) of blood in this manner is typically done at a hospital or other medicalfacility and is a relatively time consuming procedure (e.g., up to six hours orpossibly more per treatment, repeated on consecutive days, at monthly intervals)that has a substantial impact on the life of the patient undergoing the therapy.Furthermore, because photochemotherapy of blood is only available at certainmedical institutions, it may be necessary for a patient to travel some distance inorder to reach a place where the treatment can be obtained.It is impractical to provide extracorporeal photochemotherapy of blood forvery extended periods of time. Accordingly, the full potential of thephotopheresis treatment may not be realized. In addition, the patient is placed at?l0l5202530CA 02265507 2001-05-0375824-l72risk of incurring an infection each time that the treatment isperformed, since catheters conveying the blood to and from thebody are invasively connected to the ciculatory system of thepatient.Clearly, it would be much more desirable to providefor intracorporeal photopheresis of blood, using an apparatusdisposed in situ within the patient’s body. Such a devicecould be used to expose a patient’s blood to light after anappropriate photoreactive agent had been administered orally,percutanteously,or intravascularly. By employing an implanteddevice to expose the blood to light during photopheresis, apatient could remain fully ambulatory during treatment and theeffect of the treatment on the patient’s life would be minimal.More importantly, by using an implanted device to provideinternal photopheresis of the blood, the treatment canrepetitively be provided at any selected interval of time, orand with minimal risk ofif desired, on a continuous basis,infection or other adverse side effects.By administering the treatment to a patient’s bloodfor extended periods of time in situ, using various levels oflight, it is believed that improved results will be obtainedcompared to the relatively short duration conventionalextracorporeal light therapy that is currently employed.Furthermore, light sources employed in an implanted device aremuch less likely to cause damage to other components of apatient’s blood than the banks of UVA lights used in thecurrent extracorporeal apparatus, yet should be very effectivein destroying or adversely affecting malignant T—celllymphocytes or other undesired organisms or constituents in theblood.The effectiveness of light emitted by an implantedprobe for use in administering photodynamic therapy (PDT) to?lOCA 02265507 2001-05-0375824-172aabnormal tissue at internal treatment sites is disclosedincommonly assigned U.S. Patent No. 5,455,608. Each of thedifferent embodiments for the probes disclosed in thisreference includes a plurality of light sources that aremounted so that the light emitted thereby is transmitted to thecells to be destroyed by PDT. The light sources used on theprobes taught by this reference are preferably light emittingdiodes (LEDs). By transcutaneously placing one of these probesat an internal treatment site and applying PDT for an extendedtime, abnormal tissue at the treatment site can be destroyedwithout adverse impact on surrounding normal tissue. However,none of the embodiments disclosed in this patent is suitablefor?WO 98/14243101520253035CA 02265507 1999-03-08PCT/US97/14781photopheresis treatment of blood. Accordingly, a different type of device must beprovided for this purpose.Summary of the InventionIn accordance with the present invention, apparatus are de?ned foradministering intracorporeal photopheresis to blood ?owing in a patient’s body todestroy an undesirable component in the blood, where the undesirable componenthas absorbed a photoreactive agent having a characteristic light absorptionwaveband. The apparatus includes an implantable housing adapted to betranscutaneously placed at a site within a patient’s body, being made of abiocompatible material. An inlet port and an outlet port are provided in thehousing and are adapted to couple to a patient’s circulatory system to convey theblood circulated thereby into and out of the housing. A light source disposedwithin the housing emits light having a waveband substantially equal to theabsorption waveband of the photoreactive agent. Electrical current to energize thelight source is provided by a power source. A ?uid path is disposed within thehousing, adjacent to the light source and in ?uid communication with the inletport and outlet port. At least a portion of the ?uid path is optically transparent, sothat blood circulating through the ?uid path is irradiated with the light emitted bythe light source to effect the light treatment.The ?uid path preferably comprises one of several different shapedpassages, depending upon the embodiment. Various embodiments thus compriseeither a serpentine shaped passage, a helically-coiled passage, a substantiallyplanar coil, or a plurality of parallel passages extending between two headers. Inthe latter embodiment, one of the two headers is coupled to the inlet port and theother header is coupled to the outlet port.Also, different embodiments employ various types of light sources. Onesuch light source comprises a generally planar array of spaced-apart light emittingdevices, which is preferably coupled with another generally planar array ofspaced-apart light emitting devices. The arrays are disposed at opposite sides ofthe ?uid path, and the light emitting devices are directed so as to emit light towardthe ?uid path. In addition, the light emitting devices are preferably mounted on asubstantially light re?ecting surface. In another embodiment, the light sourcecomprises a bar that includes a plurality of light emitting devices, which arespaced apart generally along a longitudinal axis of the bar. In yet anotherembodiment, the light source comprises a plurality of optical ?bers that arecoupled to a light emitting device.?W0 98/ 14243101520253035CA 02265507 1999-03-08PCT/US97/ 14781In one embodiment, the power source is integral with the housing.Alternatively, however, the power source may be disposed within an" enclosurecomprising a biocompatible material and is thus adapted to be implanted withinthe patient’s body, separate from the housing for the light source.The housing may include a tab that is usable for securing the housing at adesired location within the patient’s body. For example, sutures can be threadedthrough a hole in the tab to secure the housing to an adjacent rib or other structurewithin the patient’s body. It is also desirable that the housing have a substantiallylight re?ective inner surface to improve the irradiation of blood ?owingtherethrough.To facilitate coupling the ?uid path into the patient’s circulatory system,the inlet port and the outlet port preferably comprise vascular graft tubing. Thevascular graft tubing enables a physician to suture the vascular graft tubing to theends of a transected blood vessel within the patient’s body. To avoid clotting, aninner surface of the ?uid path may be coated with a substance, such as heparin,which resists the formation of blood clots.Another aspect of the present invention is directed to a method for treatingThemethod includes steps that are generally consistent with the functions describedblood ?owing in a patient’s body to destroy an undesirable component.above in connection with the apparatus used for administering intracorporealphotopheresis of blood.Brief Description of the Drawing FiguresThe foregoing aspects and many of the attendant advantages of thisinvention will become more readily appreciated as the same becomes betterunderstood by reference to the following detailed description, when taken inconjunction with the accompanying drawings, wherein:FIGURE 1 is a perspective view, with portions broken away, showing asection of a helical coil apparatus for treating ?uids using PDT;FIGURE 2 is a top sectional view of the helical coil apparatus shown inFIGURE 1;FIGURE 3 is a perspective view of a reactor housing having serpentinetubing and a light source therein;FIGURE 4 is a top sectional view of the apparatus shown in FIGURE 3;FIGURE 5 is a side sectional view showing the reactor housing withtubing and light source installed therein;?WO 98/14243101520253035CA 02265507 1999-03-08PCT/US97/ 14781FIGURE 6 is a side sectional view of the reactor housing showing amolded shape with a plurality of parallel passages extending between an inletheader and an outlet header;FIGURE 7 is a side sectional view of a reactor housing showing an LEDgrid array light source installed therein;FIGURE 8 is a cross-sectional view of a substantially planar coil apparatusfor treating ?uids using PDT;FIGURE 9 is a side sectional view of the substantially planar coilapparatus shown in FIGURE 8;FIGURE 10 is a top perspective view, with portions in relief, showing aserpentine coil apparatus for treating ?uids using PDT with a fiber optic mat lightsource contained therein;FIGURE 11 is a side sectional view of the apparatus shown inFIGURE 10; andFIGURE 12 is a perspective view showing a biocompatible reactorhousing containing an apparatus for treating ?uids using PDT, and showing theapparatus disposed inside a patient’s rib cage.Description of the Preferred EmbodimentsAs explained above, photopheresis destroys or affects an undesirablecomponent in the blood that has absorbed a photoreactive agent having acharacteristic light absorption waveband. It is believed that improved results willbe obtained by administering the treatment to a patient's blood for extendedperiods of time in situ, using various levels of light. Moreover, relatively lowintensity light sources are much less likely to cause undesired damage to othercomponents of a patient's blood than the relatively short duration extracorporealWhile all but one of the preferredembodiments of the present invention that are described below speci?callylight therapy taught by the prior art.mention LEDs as the preferred source of light for administering PDT to blood?ow, it will be understood that other light sources are equally usable inconnection with the present invention. Such alternative light sources include, butare not limited to: laser diodes, vertical cavity surface emitting lasers (VCSELS),light emitting semiconductors, gas discharge sources, light emitting polymers, and?lament bulbs.Apparatus designed for administering photopheresis in situ, which arereferred to generally as “reactors,” are disclosed in several different embodiments,each embodiment being adapted to be transcutaneously placed at a site within a?W0 98/ 14243101520253035CA 02265507 1999-03-08PCTIUS97/14781In regard to a first embodiment of the invention, FIGUREIshows a side sectional view of a housing 100 comprising a cylindrical wall 120patient’s body.having a top end 114 and a bottom end 116 that are made of a biocompatiblematerial, such as a TEFLONTM polymer. Alternatively, the housing can befabricated from another material and coated with the biocompatible material. A?uid path intended for conveying blood through housing 100 comprisestubing 128 that is wound in a helical or cylindrical coiled shape. Tubing 128 ispreferably a transparent (or at least translucent) material of the type that can beused for blood vessel reconstruction, such as expanded reinforcedpolytetra?uoroethylene (ePTFE). Also, optically transparent materials, such aspolyvinyl chloride, polyurethane, and TEFLONTM, can be employed fortubing 128.Tubing 128 is disposed within housing 100 and has an inlet 104 and anoutlet 102, both of which are disposed outside the housing. Specifically, inlet 104is disposed where tubing 128 passes through an inlet aperture 124 formed withinhousing 100, adjacent one end, and outlet 102 is disposed where the tubing passesthrough an outlet aperture 126, adjacent the opposite end of the housing. Also, thediameters of inlet 104 and outlet 102 are preferably about 10 millimeters or less sothat they are adaptable for grafting to the ends of a severed artery, such as theinternal thoracic artery, as discussed below. Further, the diameters of inlet 104and outlet 102 can be dissimilar to affect the velocity of the blood ?ow throughhousing 100.tube 104 and outlet tube 102 both help to induce a desirable turbulence and eddycurrents in the blood ?owing through housing 100. Turbulent ?ow of bloodThe curvature of tubing 128 and dissimilar diameters of inletthrough the tubing within the housing also serves to increase the exposure to lightthat the blood passing through housing 100 receives. A light bar 108 comprisingLEDS 110 (or any of the other types of light sources noted above) and a lead 112is disposed along a center axis of tubing 128 to provide the light that irradiates theblood ?owing through the housing. An end of the light bar (or at least lead 112)passes through an aperture 118, which is axially disposed in the center of end 116of the housing. ,Tubing 128 is adapted for coupling to a patient's circulatory system by theuse of standard vascular anastomic techniques. A suitable artery having adiameter approximately equal to that of inlet 104 and outlet 102 is transected topermit the reactor to be placed in series with the two ends of the artery, so that theblood ?owing through the artery ?ows through the reactor and is exposed to the?W0 98/ 14243101520253035CA 02265507 1999-03-08PCT/U S97/ 14781light emitted by the light source contained therein. The proximal ends of inlet 104and outlet 102 preferably have a smooth pro?le to facilitate ?tting and graftingthem to the ends of the transected artery. After coupling tubing 128 to the artery,blood is circulated from the artery into the proximal end of inlet 104, passesthrough housing 100 within tubing 128, out of outlet 102, and back into the artery.LEDS 110 are energized by an electrical current conveyed throughlead 112 and emit light that irradiates the blood circulating through tubing 128.Also, an interior surface 122 of housing 100 is preferably coated or lined with are?ective material such as mirrored or white MYLARTM, or any other suitablespecular coating to improve the re?ection of light towards the blood ?owingthrough tubing 128.In FIGURE 2, housing 100 is shown from a top view, and the compactnessof its cylindrical shape is clearly evident. The compact nature of housing 100 isimportant when it is disposed at particular sites within a patient’s body havinglimited space for the placement of a medical device.Several embodiments of the present invention are illustrated inFIGURES 3 through 7. These embodiments share generally similar housings 200and 300 having an inlet 202 and an outlet 204 projecting from the center ofopposite ends of the housing in regard to the embodiment shown in FIGURES 3,4, and 5, and an inlet 302 and an outlet 304 projecting from offset points atopposite ends of a housing 300 for the embodiment shown in FIGURE 6.Housing 200 comprises a pair of sections 214 that are hermetically fastenedtogether around inlet 202 and outlet 204 and around a lead 208.although not separately shown, housing 300 also comprises sections that fittogether and seal around inlet 302, outlet 304, and a lead 324.As shown in FIGURE 7, one of the two sections 214 has an outerSimilarly,ridge 226 that circumscribes the periphery of an interior generally planarsurface 224, which is coated or lined with a re?ective material such as mirrored orwhite Mylar.respectively, inlet 202 and outlet 204. Further, a concave groove 222 in outerAn inlet groove 218 and an outlet groove 220 accommodate,ridge 226 accommodates lead 208. Also shown in this Figure is an array ofspaced-apart LEDS 212 mounted on a rectangular substrate or plate 210. In thisembodiment, the LEDS are the light source inside housing 200. Plate 210 isslightly smaller in size than section 214 and ?ts within the inside perimeter ofouter ridge 226 when it is disposed adjacent to interior surface 224.?W0 98/14243101520253035CA 02265507 1999-03-08PCT/US97/ 14781Referring now to the embodiment shown in FIGURE 5, a ?uid path isprovided through a tubing 216, that is wound in a serpentine manner comprising aseries of closely spaced half circular bends 206 that are disposed on top ofplate 210, against LEDs 212. Tubing 216 preferably comprises any of thematerials identi?ed above for tubing 128. ‘In FIGURE 4, a cross-sectional view of housing 200 is illustrated.Tubing 216 is shown disposed between a pair of plates 210 that are furtherdisposed between a pair of substantially rectangular sections 214 which are held inclose association to form housing 200.As discussed above, housing 200 is similarly adaptable for coupling to apatient's circulatory system by the use of standard vascular anastomic techniques.After housing 200 has been grafted into the patient’s circulatory system, the bloodenters the proximal end of inlet 202 and passes through serpentine tubing 216,where it is exposed to light irradiation by LED plates 210. Once irradiated, theblood exits tubing 216 through outlet 204 and re-enters the circulatory system ofthe patient.An alternative embodiment providing a different ?uid path for bloodthrough housing 300 is illustrated in FIGURE 6. A molded header manifold 306ais coupled to inlet 302, and a similar molded header manifold 306b is coupled tooutlet 304.manifolds 306a and 306b. The header manifolds and cross tubes are made of aA plurality of parallel cross tubes 308 extend between headertransparent or translucent material of the type that is commonly used for bloodvessel reconstruction, such as ePTFE. Also, optically transparent materials suchas polyvinyl chloride, polyurethane, and TEFLONTM can be employed toconstruct header manifolds 306a and 306b, and cross tubes 308.Housing 300 is constructed in a substantially similar manner ashousing 200. Housing 300 is formed from a pair of mating rectangularsections 310, each section having a concave shaped inlet groove 312, a concaveshaped outlet groove 314, a lead slot3l6, and an interior surface 318 that iscoated or lined with a re?ective material, such as mirrored or white MYLARTM.Further, light for irradiating blood ?owing through housing 300 within crosstubes 308 is provided by LEDS 212 that are energized by an electrical currentThus, LEDS 212 are the light source insidehousing 300. Sections 310 preferably comprise a biocompatible material such asconveyed through lead 324.a TEFLONTM polymer or are coated with such a material.?W0 98/ 14243101520253035CA 02265507 1999-03-08PCT/US97/14781As discussed above in connection with the first embodiment, inlet 302 andoutlet 304 are adapted for coupling to a patient's circulatory system by the use ofstandard vascular anastomic techniques. The patient's blood enters the proximalend of inlet 302 and passes through header manifold 306a into a plurality ofparallel cross tubes 308, where the blood is exposed to light produced byLEDs 212. After the light-irradiated blood has passed through cross tubes 308,the blood enters header manifold 306b and leaves housing 300 through outlet 304to re-enter the circulatory system of the patient.Yet another alternative embodiment is illustrated in FIGURES 8 and 9.This embodiment includes a housing 400, which is generally disk shaped andcomprises a top section 414 that is affixed to a similarly shaped bottomsection 412. Between top section 414 and bottom section 412 is disposed a coil oftubing 406, which is wound in a substantially planar spiral. Tubing 406 is madeof the same materials identified for tubing in the embodiments discussed above.Extending downwardly through bottom section 412 from an inner end of thespiraled tubing is an inlet 402; an outlet 404 extends radially outwardly throughhousing 400 from the outer end of the spiral. Generally round plates 408 and 424are respectively mounted inside bottom section 412 and top section 414, so that anarray of spaced-apart LEDs (not separately shown), which are mounted thereon,are disposed adjacent opposite sides of tubing 406. The LEDS are energized withan electrical current conveyed through a lead 410 from a suitable internal (orexternal power source (not shown). Plate 408 is slightly smaller in size thanbottom section 412 and fits within the inside perimeter of a bottom outsidelip 420, against an interior surface 418. Similarly, plate 424 is slightly smaller insize than top section 414 and fits within the inside perimeter of a top outsidelip 426. A top outer surface 435 and a bottom outer surface 436 of housing 400are preferably composed of a biocompatible material such as a TEFLONTMpolymer. Also, a top interior surface 428 and bottom interior surface 418 arecoated or lined with a re?ective material such as mirrored or white MYLARTM toimprove the re?ection of light towards the blood ?owing through tubing 406.Tubing 406 passes through a round inlet aperture 430, which is disposed inthe center of bottom section 412. Further, tubing 406, by passing through anaperture comprising a concave groove 434 formed in top section 414, and aconcave groove 432 that is formed in bottom section 412. Also, lead 410 entershousing 400 through an aperture comprising a slot 422 and a slot 416, which arerespectively formed in the top and bottom sections.?W0 98/14243101520253035CA 02265507 1999-03-08PCT/US97/ 14781-10-As discussed above in connection with the other embodiments, inlet 402and outlet 404 are adapted for coupling to a patient's circulatory system by the useof standard vascular anastomic techniques. The patient's blood enters theproximal end of tubing 406 through inlet 402 and passes through tubing 406within housing 400, where the blood is exposed to light emitted by the lightsources mounted on plates 408 and 424. After the light irradiated blood haspassed through tubing 406, the blood exits housing 400 through outlet 404 andre-enters the circulatory system of the patient.Yet another embodiment of the present invention is illustrated inFIGURES 10 and 11. In this embodiment, a housing 600 is coupled to an externallight source 504 through a bundle 500 of optical ?bers 506. Bundle 500 isdivided into planar arrays 604 and 608, each of which includes optical ?bers 506that enter housing 600 along one side of either a top section 606 or a bottomsection 602, at spaced-apart points. Ends of optical fibers 506 comprising planararray 604 are terminated along one edge of a top mat 508. Similarly, ends ofoptical ?bers 506 comprising planar array 608 are terminated along one edge of abottom mat 510. Thus, light conveyed through the optical ?bers passes throughthe ends of the optical ?bers and is diffused through the top and bottom mats. Thelight conveyed through the top and bottom mats irradiates blood ?owing througha path within housing 600. Tubing 216, having a serpentine shape, is shownwithin housing 600 in the Figures; however, the optical ?bers can be used toconvey light that irradiates blood ?owing through any of the other con?gurationsfor a ?uid path through any of the reactors that are discussed above.In FIGURE 11, the tubing conveying blood is disposed between topmat 508 and bottom mat 510, respectively within top section 606 and bottomsection 602. Since top mat 508 and bottom mat 510 convey light received fromoptical ?bers 506, which is produced by external light source 504, the top andbottom mats have a much lower operating temperature than a light source that isincluded inside any of the housings discussed above. Additionally, a top interiorsurface 612 and a bottom interior surface 610 are coated or lined with a re?ectivematerial such as white or mirrored MYLARTM to enhance the delivery of light tothe blood ?owing through the reactor. Also, a top outside surface 616 and abottom outside surface 614 are typically fabricated of or coated with abiocompatible material such as TEFLONTM.While any of the embodiments of the present invention discussed abovecan be implanted at other sites within a patient’s body, a particularly suitable site?W0 98/ 14243101520253035CA 02265507 1999-03-08PCT/US97/ 14781-11-is within the thoracic cavity, adjacent to the sternum. This site provides access tothe internal thoracic artery, which can readily be transected to enable the reactor tobe attached in series with the transected ends of the artery, without signi?cantadverse effects on the patient. In the implantation process, which is illustrated inFIGURE 12, the left third true rib is removed and costal cartilage 718 is trimmedto accommodate the positioning of a housing 700 within the resulting cavity.Housing 700 is intended to be merely representative of the housings of any of theembodiments discussed above. An inlet 714 and an outlet 716, which are alsorepresentative of the inlet and outlet for any of the embodiments discussed above,extend from the housing and are attached to the ends of severed internal thoracicartery 726 at a top suture line 724 and a bottom suture line 722, so that blood?owing through the internal thoracic artery is shunted through housing 700. Oncehousing 700 is tied into the patient’s circulatory system and securely positioned asdescribed below, PDT can be administered to the blood ?owing through thereactor on either a continuous or intermittent basis, simply by energizing the lightsource(s).The housings of any of the embodiments discussed above may include oneor more tabs for securing the housing to a desired location within the patient’sbody. In FIGURE 12, housing 700 has tabs disposed on three of its four edges. Atop tab 704 is disposed on the top edge of housing 700 and has an aperture 706through which a suture 708 is threaded. A costal cartilage 710 for the left secondtrue rib is perforated to form a suture aperture 712 through which suture 708 islooped and tied to secure housing 700. This attachment procedure is optionallyrepeated for a bottom tab 702 that is disposed on the bottom edge of housing 700.Bottom tab 702 has an aperture 740 through which a suture 728 is threaded.Subsequently, a costal cartilage 730 for the left fourth true rib is perforated toform a suture aperture 732 through which suture 728 is looped and tied to securelyposition housing 700. The attachment of a side tab 734 to a patient’s body isSide tab 734 has an aperture 736 throughwhich a suture 738 is threaded. Trimmed costal cartilage 718 is perforated toaccomplished in a similar manner.form a suture aperture 720 through which suture 738 is looped and tied to securelyposition housing 700 within the patient’s body.All of the leads in the various embodiments are connected to a matchedpower supply 800 capable of supplying an electrical current to energize thevarious types of light sources discussed above. Power supply 800 is preferably anintracorporeal device that is disposed in situ near the reactor, however, it may also?W0 98/ 14243101520253035CA 02265507 1999-03-08PCT/U S97/ 14781-12-be located external to the patient’s body. Further, the power supply can bedisposed within the housing to provide the electrical current necessary to energizethe light sources. In any case, the power supply can comprise a rechargeableand/or be source thatbattery inductively coupled to an externalelectromagnetically supplies power to the internal power supply.Although not shown in any of the embodiments described herein,electroluminescent panels can be used as the source of light that irradiates blood?owing through any of the reactor housings. These panels would be disposed onopposite sides of the path along which blood ?ows through the housing.The light sources described in the various embodiments above irradiate thepatient’s blood from a location inside the reactor housing. However, the lightsources can be coupled to the exterior surface of the reactor so that the blood?owing through a ?uid within the housing irradiated with light from the sourcesthat passes through a transparent (or at least translucent) housing. An externallypositioned light source could also have a backing that is coated or lined with are?ective material such as white or mirrored MYLARTM to enhance the deliveryof light to the blood ?owing through the reactor.Another aspect of the present invention is directed to reducing skinphotosensitivity that can occur as a result of intravenous drug delivery of thephotosensitizer. The photosensitizer may be administered intra-arterially using adrug pump that injects the photosensitizer into the patient’s circulatory system at apoint that is just proximal to the site of the reactor. With this approach, the drugshould be mostly photobleached by the light administered in the housing beforethe drug exits the reactor. A reservoir of the photosensitizer drug could also becoupled by a tube to the inlet of the reactor and allowed to elute into the blood?ow via a porous tip.An inherent advantage of the present invention is that excessive heatbuildup from the light source is prevented by the continual ?ow of blood throughthe housing. The total length of the ?uid path through the housing extends thecirculation time of the patient’s blood within the reactor and thus prolongs theduration of the PDT. Further, the proper selection and targeting of photosensitizerdrugs may cause selective binding to occur to the pathogen and avoidphotodynamic injury to normal blood constituents.An added bene?t is that the photodynamic ‘action on the inner wall of thefluid path through the reactor housing may prevent intimal hyperplasia, whichcould lead to failure of the graft of a blood vessel to the inlet or outlet of the?W0 98/ 1424310CA 02265507 1999-03-08PCT/US97/14781-13-reactor. Also, the inner walls of the ?uid path through which blood ?ows throughthe reactor may be lined with an anti-coagulant, such as heparin, so as to preventthe clotting of blood cells in the housing. However, it is possible that simplyadministering a low dose of aspirin after the reactor is implanted may providesuf?cient thinning of the blood to prevent clotting within the ?uid path of thereactor.Although the present invention has been described in connection with thepreferred form of practicing it, those of ordinary skill in the art will understandthat many modifications can be made thereto within the scope of the claims thatfollow. Accordingly, it is not intended that the scope of the invention in any waybe limited by the above description, but instead be determined entirely byreference to the claims that follow.

Claims (16)

The invention in which an exclusive right is claimed is defined by the following:

1. Apparatus for administering intracorporeal photopheresis to blood flowing in a patient's body to destroy or affect an undesirable component in the blood, where the undesirable component has absorbed a photoreactive agent having a characteristic light absorption waveband, said apparatus comprising:
(a) an implantable housing adapted to be transcutaneously placed at a site within a patient's body, said implantable housing comprising a biocompatible material and having an inlet port and an outlet port adapted to couple to a patient's circulatory system to convey the blood circulated thereby into and out of the housing;
(b) a light source coupled to the housing, said light source emitting light within a waveband substantially equal to the absorption waveband of the photoreactive agent;
(c) a power source for supplying an electrical current to energize said light source; and (d) a fluid path disposed within the housing adjacent to the light source and in fluid communication with said inlet port and said outlet port, at least a portion of said fluid path being optically transparent, so that blood circulating through the fluid path is irradiated with the light emitted by said light source to effect the light treatment, said blood circulating through the fluid path sufficiently fast to avoid heat build up that might otherwise harm the blood.

2. The apparatus of Claim 1, wherein the fluid path comprises a serpentine shaped passage.

3. The apparatus of Claim 1, wherein the fluid path comprises a helically coiled passage.

4. The apparatus of Claim 1, wherein the fluid path is a substantially planar coil.

5. The apparatus of Claim 1, wherein the fluid path comprises a plurality of parallel passages extending between two headers, one of said two headers being coupled to the inlet port and another of the two headers being coupled to the outlet port.

6. The apparatus of Claim 1, wherein the light source comprises one of a first generally planar array of spaced-apart light emitting devices and a luminescent panel.

7. The apparatus of Claim 6, wherein the light source further comprises a second generally planar array of spaced-apart light emitting devices, said first and said second arrays being disposed at opposite sides of the fluid path with the light emitting devices being directed to emit light toward the fluid path.

8. The apparatus of Claim 6, wherein the light emitting devices are mounted on a substantially light reflecting surface.

9. The apparatus of Claim 1, wherein the light source comprises a bar that includes a plurality of light emitting devices that are spaced apart generally along a longitudinal axis of the bar.

10. The apparatus of Claim 1, wherein the light source comprises a plurality of optical fibers coupled to a light emitting device.

11. The apparatus of Claim 1, wherein the power source is integral with the housing.

12. The apparatus of Claim 1, wherein the power source is disposed within an enclosure comprising a biocompatible material and is thus adapted to be implanted within the patient's body, separate from the housing.

13. The apparatus of Claim 1, wherein the housing includes a tab usable for securing the housing at a desired location within the patient's body.

14. The apparatus of Claim 1, wherein the housing has a substantially light reflective inner surface.

15. The apparatus of Claim 1, wherein the inlet port and the outlet port comprise vascular graft tubing.

16. The apparatus of Claim 1, wherein an inner surface of the fluid path is coated with a medicinal substance that resists formation of blood clots.